NCT01611155View on ClinicalTrials.gov

Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 17, 2012

Primary Completion Date

March 7, 2014

Study Completion Date

September 23, 2015

Conditions
Peripheral Neuropathy
Interventions
DRUG

venlafaxine

Given PO

DRUG

placebo

Given PO

OTHER

questionnaire administration

Ancillary studies

OTHER

quality-of-life assessment

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01611155 - Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy | Biotech Hunter | Biotech Hunter